Luzzi S, Crovace AM, Del Maestro M et al (2019) The cell-based approach in neurosurgery: ongoing trends and future perspectives. Heliyon 5(11):e02818. https://doi.org/10.1016/j.heliyon.2019.e02818

Article  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl) 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1

Article  PubMed  Google Scholar 

Wang Q, Duan F, Wang MX, Wang XD, Liu P, Ma LZ (2016) Effect of stem cell-based therapy for ischemic stroke treatment: A meta-analysis. Clin Neurol Neurosurg 146:1–11. https://doi.org/10.1016/j.clineuro.2016.04.011

Article  PubMed  Google Scholar 

Bausart M, Préat V, Malfanti A (2022) Immunotherapy for glioblastoma: the promise of combination strategies. J Exp Clin Cancer Res CR 41(1):35. https://doi.org/10.1186/s13046-022-02251-2

Article  CAS  PubMed  Google Scholar 

Wainwright DA, Sengupta S, Han Y, Lesniak MS (2011) Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors. Neuro-Oncol 13(12):1308–1323. https://doi.org/10.1093/neuonc/nor134

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wainwright DA, Dey M, Chang A, Lesniak MS (2013) Targeting Tregs in malignant brain cancer: overcoming IDO. Front Immunol 4:116. https://doi.org/10.3389/fimmu.2013.00116

Article  PubMed  PubMed Central  Google Scholar 

Krucoff MO, Miller JP, Saxena T et al (2019) Toward functional restoration of the central nervous system: A review of translational neuroscience principles. Neurosurgery 84(1):30–40. https://doi.org/10.1093/neuros/nyy128

Article  PubMed  Google Scholar 

Campanella R, Guarnaccia L, Caroli M et al (2020) Personalized and translational approach for malignant brain tumors in the era of precision medicine: the strategic contribution of an experienced neurosurgery laboratory in a modern neurosurgery and neuro-oncology department. J Neurol Sci 417:117083. https://doi.org/10.1016/j.jns.2020.117083

Article  PubMed  Google Scholar 

Eramo A, Ricci-Vitiani L, Zeuner A et al (2006) Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13(7):1238–1241. https://doi.org/10.1038/sj.cdd.4401872

Article  CAS  PubMed  Google Scholar 

Scott J, Tsai YY, Chinnaiyan P, Yu HHM (2011) Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 81(1):206–210. https://doi.org/10.1016/j.ijrobp.2010.04.033

Article  PubMed  Google Scholar 

Mrugala MM (2013) Advances and challenges in the treatment of glioblastoma: a clinician’s perspective. Discov Med 15(83):221–230

PubMed  Google Scholar 

Rich JN, Bigner DD (2004) Development of novel targeted therapies in the treatment of malignant glioma. Nat Rev Drug Discov 3(5):430–446. https://doi.org/10.1038/nrd1380

Article  CAS  PubMed  Google Scholar 

Haar CP, Hebbar P, Wallace GC 4th et al (2012) Drug resistance in glioblastoma: a mini review. Neurochem Res 37(6):1192–1200. https://doi.org/10.1007/s11064-011-0701-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohka F, Natsume A, Wakabayashi T (2012) Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int 2012:878425. https://doi.org/10.1155/2012/878425

Article  PubMed  PubMed Central  Google Scholar 

Bonosi L, Marrone S, Benigno UE et al (2023) Maximal safe resection in glioblastoma surgery: A systematic review of advanced intraoperative Image-Guided techniques. Brain Sci 13(2). https://doi.org/10.3390/brainsci13020216

Sulangi AJ, Husain A, Lei H, Okun J (2024) Neuronavigation in glioma resection: current applications, challenges, and clinical outcomes. Front Surg 11:1430567. https://doi.org/10.3389/fsurg.2024.1430567

Article  PubMed  PubMed Central  Google Scholar 

de Gooijer MC, de Vries NA, Buckle T et al (2018) Improved brain penetration and antitumor efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia N Y N 20(7):710–720. https://doi.org/10.1016/j.neo.2018.05.001

Article  CAS  Google Scholar 

Messaoudi K, Clavreul A, Lagarce F (2015) Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to Temozolomide. Drug Discov Today 20(7):899–905. https://doi.org/10.1016/j.drudis.2015.02.011

Article  CAS  PubMed  Google Scholar 

Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M (2018) Potential strategies overcoming the Temozolomide resistance for glioblastoma. Neurol Med Chir (Tokyo) 58(10):405–421. https://doi.org/10.2176/nmc.ra.2018-0141

Article  PubMed  Google Scholar 

Thiruvengadam M (2024) Radioresistance in brain tumors: strategies for improved radiotherapy outcomes. Brain Spine 4:102912. https://doi.org/10.1016/j.bas.2024.102912

Article  PubMed  PubMed Central  Google Scholar 

Ghosh S, Huang J, Inkman M et al (2023) Radiation-induced Circulating myeloid-derived suppressor cells induce systemic lymphopenia after chemoradiotherapy in patients with glioblastoma. Sci Transl Med 15(680):eabn6758. https://doi.org/10.1126/scitranslmed.abn6758

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE (2015) Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother 19:1–12. https://doi.org/10.1016/j.drup.2015.02.002

Article  Google Scholar 

Comprehensive genomic characterization (2008) Defines human glioblastoma genes and core pathways. Nature 455(7216):1061–1068. https://doi.org/10.1038/nature07385

Article  CAS  Google Scholar 

Nagane M (2011) Neuro-oncology: continuing multidisciplinary progress. Lancet Neurol 10(1):18–20. https://doi.org/10.1016/S1474-4422(10)70302-1

Article  PubMed  Google Scholar 

Rajaratnam V, Islam MM, Yang M, Slaby R, Ramirez HM, Mirza SP (2020) Glioblastoma: pathogenesis and current status of chemotherapy and other novel treatments. Cancers 12(4). https://doi.org/10.3390/cancers12040937

Lefrère JJ, Berche P (2010) [Doctor Brown-Sequard’s therapy]. Ann Endocrinol 71(2):69–75. https://doi.org/10.1016/j.ando.2010.01.003

Article  Google Scholar 

Raysi Dehcordi S, Ricci A, Di Vitantonio H et al (2017) Stemness marker detection in the periphery of glioblastoma and ability of glioblastoma to generate glioma stem cells: clinical correlations. World Neurosurg 105:895–905. https://doi.org/10.1016/j.wneu.2017.05.099

Article  PubMed  Google Scholar 

Palumbo P, Lombardi F, Siragusa G et al (2018) Involvement of NOS2 activity on human glioma cell growth, clonogenic potential, and neurosphere generation. Int J Mol Sci 19(9). https://doi.org/10.3390/ijms19092801

Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872. https://doi.org/10.1016/j.cell.2007.11.019

Article  CAS  PubMed  Google Scholar 

Yu J, Vodyanik MA, Smuga-Otto K et al (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917–1920. https://doi.org/10.1126/science.1151526

Article  CAS  PubMed  Google Scholar 

Tesileanu CMS, Dirven L, Wijnenga MMJ et al (2020) Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncol 22(4):515–523. https://doi.org/10.1093/neuonc/noz200

Article  CAS  PubMed  Google Scholar 

Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic Astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (Berl) 120(6):707–718. https://doi.org/10.1007/s00401-010-0781-z

Article  PubMed  Google Scholar